Aptose Biosciences Inc.

Posters & Presentations

All Poster Presentation
December 9, 2024 Poster

Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML

Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML: View Poster
November 7, 2024 Presentation

Aptose Corporate Presentation November 2024

Aptose Corporate Presentation November 2024: View Presentation
July 26, 2024 Presentation

Aptose Corporate Presentation July 2024

Aptose Corporate Presentation July 2024: View Presentation
June 14, 2024 Poster

2024 EHA Poster – Tuspetinib Retains Nanomolar Potency Against AML Cells Engineered to Express the NRAS G12D Mutation or Selected for Resistance to Venetoclax

2024 EHA Poster – Tuspetinib Retains Nanomolar Potency Against AML Cells Engineered to Express the NRAS G12D Mutation or Selected for Resistance to Venetoclax: View Poster
June 14, 2024 Poster

2024 EHA Poster – Safety and Efficacy of Tuspetinib as Monotherapy and Combined with Venetoclax in a Phase 1/2 Trial of Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

2024 EHA Poster – Safety and Efficacy of Tuspetinib as Monotherapy and Combined with Venetoclax in a Phase 1/2 Trial of Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML): View Poster
May 3, 2024 Presentation

Aptose Corporate Presentation May 2024

Aptose Corporate Presentation May 2024: View Presentation
December 26, 2023 Presentation

Aptose Corporate Presentation December 2023

Aptose Corporate Presentation December 2023: View Presentation
December 9, 2023 Presentation

Tuspetinib Oral Myeloid Kinase Inhibitor Safety and Efficacy As Monotherapy and Combined with Venetoclax in Phase 1/2 Trial of Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Tuspetinib Oral Myeloid Kinase Inhibitor Safety and Efficacy As Monotherapy and Combined with Venetoclax in Phase 1/2 Trial of Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML): View Presentation
October 30, 2023 Presentation

Tuspetinib Clinical Update and KOL Data Review

Tuspetinib Clinical Update and KOL Data Review: View Presentation